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Background: Opioids are psychoactive analgesic drugs prescribed for pain relief and palliative care. Due to their
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opioid dependence.
Methods/Design: The authors will search Medline, EMBASE, PubMed, PsycINFO, Web of Science, Cochrane Library,
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retention and response to treatment (as measured through continued opioid abuse).
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Opioids are psychoactive analgesic drugs prescribed for
pain relief and palliative care [1]. Due to their addictive
nature, effort and vigilance in controlling prescriptions is
needed to avoid misuse and dependence. Despite such
effort, opioid use disorder is commonly associated with
both illicit and prescription opioid use [2]. The DSM-5
characterizes opioid use disorder as a ‘problematic pattern
of opioid use leading to clinically significant impairment
or distress’ [3]. Characteristics of opioid use disorder in-
clude increased tolerance, continued use despite personal
and social problems, as well as withdrawal and tolerance,
among other behavioral changes [3]. Opioid use has been
on the rise for the past several years, although common
and available treatment options have not adjusted to meet
the increasing demand for therapy [4].
The rapid rise in opioid prescriptions worldwide in
conjunction with the increase in misuse and addiction is
concerning [2,5]. Opioid-related deaths in ON, Canada
have doubled between 1991 and 2004 [6,7]. In the
United States, opioid sales have surged 627% between
1997 and 2007 [8]. Accompanying this dramatic rise in
prescription opioid sales, the number of opioid-related
overdoses in the United States has increased tenfold
since 1990 [9]. Aside from the negative impact of drug
use on the patient's lifestyle and psychological state,
many physical health issues are associated with opioid
abuse. For instance, IV opioid use is found to be associ-
ated with serious cardiac abnormalities such as infective
endocarditis [10,11]. Furthermore, opioid use has been
correlated with increase HIV risk and susceptibility to
other opportunistic infections such as hepatitis C and
tuberculosis [12].
Today, opioid substitution treatment (OST) is used to
treat opioid dependence. This medical intervention em-
ploys strategies to control rather than prevent drug use
in attempts to limit the incidence of adverse events. This
involves prescribing controlled amounts of longer acting
but less euphoric opioids to reduce cravings and prevent
withdrawal symptoms [13]. Currently, the most commonly
used substitute opioid is methadone [14,15]. First intro-
duced for the treatment of opioid use disorder in 1965,
methadone maintenance treatment (MMT) has been
shown to be effective in ameliorating symptoms of
opioid craving and reducing the negative effects that
illicit drug use has on individuals, such as increased
HIV risk [16]. It has also been shown to alleviate some
of the burden that illicit drug use places on society,
including criminal acts and the spread of infectious
disease to others [15,17-21]. Reported methadone ef-
fectiveness varies by studies, with some investigations
reporting as low as 20% to as high as 70% [10-12]. These
rates are largely accounted for by the numerous defini-
tions of methadone effectiveness reported in the literature.Interindividual variability in clinical responses to metha-
done and dose requirements depend on several factors in-
cluding age, diet, metabolism, protein binding, medications,
genetic variants, and other substance use [22-26].
MMT is used by 20%–25% of opioid-dependent indi-
viduals in North America, leaving approximately 75% of
the opioid-dependent population on another intervention
or without any treatment at all [27]. While methadone is
claimed to be an effective treatment for patients with opi-
oid use disorder, it is important to note that alternative
therapies are on the rise. Suboxone® is a relatively new
drug approved in Canada since 2007, comprised of a
combination of buprenorphine and naloxone in a 4:1
ratio [28]. When taken sublingually, only buprenorphine
exerts its partial agonistic effects because naloxone is
not adequately absorbed. However, in case of parenteral
abuse, the administration naloxone exerts a withdrawal
effect in opioid-dependent patients [29,30]. Therefore,
the role of this combination is to ultimately alleviate
withdrawal symptoms while also deterring intravenous
use of the medication. Suboxone's effects are less prom-
inent than full opioid agonists, as such it induces less
physical dependence than other full opioid agonists
such as heroin, morphine, and methadone [31]. It is also
associated with less dysphoric effects than methadone,
encouraging a greater portion of patients to continue in
treatment. As well, it has a ceiling effect, such that its
effectiveness remains constant beyond a certain dose, thus
helping to control use and limit abuse [32].
According to one study, buprenorphine/naloxone pa-
tients reported significantly improved social life, edu-
cational level, and response to treatment (measured
through urine toxicology screens), as compared to patients
on MMT [33]. However, further studies including a
17-week randomized single-center trial reported no
significant difference in the proportion of opioid-negative
urine samples between patients on buprenorphine relative
to methadone [31].
Naltrexone, another alternative opioid substitution
therapy, is a competitive opioid receptor antagonist that
blocks the euphoric effects of opioids by acting on recep-
tors in the brain [34]. The oral form has been available
since 1980s but due to the lack of patients' adherence to
the therapy, it has been deemed ineffective until the recent
introduction of long-acting injections and implants of nal-
trexone [34]. Long-lasting injectable naltrexone therapy
was approved by the FDA in 2010 after a 6-month
placebo-controlled trial showed that over 50% of pa-
tients remained on treatment and refrained from using
illicit drugs for the entire study period [34,35]. A double-
blinded randomized controlled trial (RCT) (n = 60) investi-
gating the efficacy of injectable naltrexone against placebo
demonstrated a significantly reduced ‘need’ for heroin, as
per patient reporting, after treatment (192 or 384 mg) in
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ister, does not induce tolerance over time, and it is not
addictive [37].
However, naltrexone removes tolerance to opioids and
thus increases the risk of overdose should patients
choose to abstain from therapy and return to illicit opi-
oid use. According to a search of the National Coronial
Information System (2000–2003), deaths associated with
oral naltrexone use are three to seven times higher than
those of methadone [38].
Heroin-assisted therapy (HAT) is a novel and contro-
versial treatment for opioid dependence which involves
the administration of injectable diacetylmorphine, the
active ingredient of heroin. HAT is more effective than
oral methadone in terms of both reduction of illicit drug
use (67.0% and 47.7%) and increase in retention in treat-
ment (87.8% vs 54.1%). A study by Oviedo-Joekes et al.
has shown that HAT is slightly more effective than
methadone for increasing quality of life years gained
(7.46 vs 7.92) [39]. As well, the study shows that HAT is
more cost effective in terms of long-term incurred societal
costs compared to methadone, primarily due to the fact
that patients adhere to treatment longer and are less likely
to relapse, resulting in less criminal activity [40].
Due to the aforementioned concerns and inconsistent
findings related to the effectiveness of OSTs currently
available, it is important to determine the most effective
OST for increasing patient retention and restraining
illicit opioid use. This systematic review will investigate
the effectiveness of methadone, buprenorphine/naloxone,
naltrexone, heroin-assisted therapy (HAT) and any other
OST in terms of the continued opioid use (response to
treatment) retention in treatment, physical and psycho-
logical well-being, social implication (criminal activity), as
well as incidence of adverse events or toxic effects from
the opioid intervention.
Objectives
This systematic review aims to assess and compare the
effectiveness of all available OSTs in the treatment of
opioid use disorder, including but not limited to
methadone, buprenorphine/naloxone (Suboxone®), nal-
trexone, and heroin (diacetylmorphine)-assisted therapy.
Specifically, the objectives of this investigation include:
1) Assessing the effectiveness of the aforementioned
therapies based on retention in treatment and
continued opioid use (response to treatment).
2) Conduct direct comparisons using random
effects meta-analytic models and when
appropriate, conduct a network meta-analysis to
synthesize a mean difference, relative risk, or
odds ratio that encompasses results from
multiple studies.3) Critically evaluate current literature and identify
important areas of addiction medicine that future
research should address.
4) Offer unbiased report of the effectiveness of
different treatments in relation to one another to
enhance current clinical treatment of opioid use
disorders.
Research question
Among patients being treated for opioid use disorder,
which OST (methadone, buprenorphine/naloxone, nal-
trexone, HAT, and/or other) is most effective for
increasing retention in treatment and restraining con-
tinued opioid use?
Methods/Design
Data sources and search strategy
In order to conduct a comprehensive search of the
available literature, we will use a set of predetermined
and separate key terms to search the following online
databases: Medline, EMBASE, PubMed, PsycINFO,
Web of Science, Cochrane Library, Cochrane Clinical
Trials Registry, World Health Organization (WHO)
International Clinical Trials Registry Platform Search
Portal, and the National Institutes for Health (NIH)
Clinical Trials Registry. Searches will be performed
independently by two authors (LN and BD). The au-
thors will perform additional manual searches of all
completed Cochrane reviews examining the effect of
different OSTs. The manual search will be used to
identify any RCT or observational study on OSTs that
have been combined statistically and narratively in a
Cochrane review, as Cochrane is the leader and gold
standard in systematic reviews. We will also contact
each primary investigator listed on the NIHs Clinical
Trial Registry from studies deemed eligible during the
title screening, where we will inform the investigators
of our review and ask for information regarding any
publications resulting from their trial. We will also
contact a librarian from the McMaster Faculty of
Health Sciences Library with expertise in systematic
reviews throughout the process of devising the search
strategy and conducting the literature search. The two
authors (LN and BD) will then independently refer to
the bibliographies of articles that pass the initial ab-
stract screening. No constraints will be set on language
or date of publication in order to allow for a more thor-
ough search of the literature. However, only human stud-
ies will be included. As well, we will eliminate incomplete
studies, as they would not provide sufficient data for ex-
traction. We will inform the authors of the eligible articles
about the review during the data extraction process to
consult them for clarification of their data when needed.
Please refer to Table 1 for full search strategy.
Table 1 Defined search strategy for the extraction of pertinent studies from multiple databases
CINAHL search strategy search = ___ 1. (MH ‘methadone+’)
2. (MH ‘suboxone+’)
3. (MH ‘heroin assisted treatment+’)
4. (MH ‘diacetylmorphine+’)





10. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9
11. (MH ‘disorder, substance abuse’) or (MH ‘substance withdrawal
syndrome+’) or (MH ‘substitute opioid therapy+’)
12. 10 AND 11
Medline search strategy search = ____ 1. methadone/th [Therapy]
2. limit 1 to humans
3. opioid substitution treatment/ae mo [adverse effects, mortality]
4. limit 3 to humans
5. substance-Related Disorders/de, ep, th [Drug Effects, Epidemiology,
Therapy]
6. Limit 5 to humans
7. Opiate Substitution Treatment/or Naloxone/or Buprenorphine/or
Opioid-Related Disorders/or Heroin Dependence/or Substance
Withdrawal Syndrome/or Narcotic Antagonists/
8. Limit 7 to humans
9. Naltrexone/ae, ag, ai, tu [Adverse Effects, Agonists, Antagonists &
Inhibitors, Therapeutic Use]
10. Limit 9 to humans
11. Substance Abuse Treatment Centers/or Substance Abuse, Intravenous/
or Heroin/or Heroin Dependence/or Opioid-Related Disorders/or
Randomized Controlled Trials as Topic/or Methadone/
12. Limit 11 to humans
13. methadone/
14. limit 13 to humans
15. 2 OR 4 OR 8 OR 10 OR 12 OR 14
16. 15 AND 6
Web of science search strategy search = _____ 1. Topic = (‘methadone’ OR ‘methadone maintenance therapy’ OR
‘naltrexone’ OR ‘suboxone’ OR ‘buprenorphine’ OR ‘heroin assisted
treatment’)
2. Topic = (‘substitute opioid therapy’ OR ‘opioid substitution therapy’)
3. 1 AND 2
EMBASE search strategy Search = ___ 1. methadone treatment/or methadone/or methadone plus naloxone/
2. limit 1 to human
3. buprenorphine plus naloxone/
4. limit 3 to human
5. morphine sulfate plus naltrexone/or naltrexone/
6. limit 5 to human
7. opiate addiction/or heroin dependence/or methadone/or diamorphine/
8. limit 7 to human
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Table 1 Defined search strategy for the extraction of pertinent studies from multiple databases (Continued)
9. opiate substitution treatment/ae [Adverse Drug Reaction]
10. methadone/or buprenorphine/or opiate addiction/or substitute
opioid therapy.mp.
11. 9 or 10
12. 2 or 4 or 6 or 8
13. 11 and 12
14. substance abuse/or addiction/or drug dependence/
15. 13 and 14
16. randomized controlled trial/
17. 15 and 16
PsycINFO search strategy search = _____ 1. exp Methadone Maintenance/or exp Methadone/
2. limit 1 to human
3. exp Treatment Outcomes/or exp Drug Therapy/or exp Methadone
Maintenance/or exp Drug Dependency/or exp Maintenance Therapy/or
exp Methadone/or exp Heroin/
4. limit 3 to human
5. exp Drug Addiction/or exp Clinics/or exp Drug Therapy/or exp Drug
Dependency/or exp ‘Recovery (Disorders)’/or exp Maintenance Therapy/
6. limit 5 to humans
7. exp naltrexone/
8. limit 7 to humans
9. exp Maintenance Therapy/or exp Naloxone/or exp Drug Therapy/or
exp Drug Dependency/or exp Heroin Addiction/
10. limit 7 to humans
11. exp Treatment Outcomes/or exp Clinical Trials/or exp Drug Therapy/
or exp Heroin Addiction/or exp Methadone Maintenance/
12. limit 9 to humans
13. 2 and 8 and 10
14. 2 and 10
15. 2 and 12
16. 2 and 6 and 12
17. 13 or 14 or 15 or 16
Cochrane library search strategy search = __ 1. search title, abstract, keywords: methadone
2. search title, abstract, keywords: buprenorphine
3. search title, abstract, keywords: naltrexone
4. search title, abstract, keywords: heroin assisted treatment
Clinical Trials Registry through National Institutes for Health search
strategy Search = ____
‘methadone’ OR ‘suboxone’ OR ‘Buprenorphine’ OR ‘substitute opioid therapy’
OR ‘naltrexone’ OR ‘heroin assisted treatment’ OR ‘heroin adjustment therapy’
AND ‘opioid addiction’, with additional criteria including: Completed studies,
exclude unknown status, adult age requirements, and all trials had to be
listed as Phase 3, 4
Cochrane Central Register of Controlled Trials search strategy
Search = ____
‘substitute opioid therapy’ OR ‘methadone’ OR ‘naltrexone’ OR ‘buprenorphine’
OR ‘heroin assisted treatment’ OR ‘heroin adjustment therapy’ in title abstract
keywords and opioid addiction in title abstract keywords in Trials
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The authors (LN and BD) will independently conduct a
primary title search, title screening, abstract screening,
and full-text extraction. We will refer to the inclusion
and exclusion criteria throughout the screening process.All data extraction forms will be pilot tested before use.
In the case of a disagreement during the search and
selection process, we will engage in a discussion to reach
a mutual agreement. However, should the conflict persist,
we will resort to a third author (ZS) to facilitate the
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assessed using the kappa statistic [41]. As per guidelines
set by the Meta-analysis of Observational Studies in Epi-
demiology (MOOSE) and the Preferred Reporting Items
for Systematic Reviews and Meta-Analyses (PRISMA), we
will include both a flow diagram displaying screening
process (Figure 1) and a detailed table of the studies se-
lected in the systematic review [42,43].
Inclusion and exclusion criteria
The authors will limit the studies included in this review
to RCTs and observational studies evaluating the effective-
ness of methadone, buprenorphine/naloxone, naltrexone,
HAT, and/or any other unlisted OST for the treatment of
opioid dependence. The study will have had to examine
the effectiveness of one of the aforementioned treatments
with one or more of the outcomes of interest: retention in
treatment, response to treatment (as measured through
continued opioid use), criminal activity (as measured by
self-report), mortality, physical and psychological health,
as well as incidence of toxic and adverse events. No age
restrictions will be set. In addition, we will also excludeFigure 1 Flow diagram of screening process.articles examining specialized populations such as pris-
oners examined within penitentiaries or other settings as
well as pregnant women. All studies must also be primary
investigations with comparison groups (separated by a
treatment or placebo), we will not allow studies such as
case reports or case series to be included in the review, ar-
guably due to their lack of an appropriate comparison
group. We have noted that we are primarily interested in
patient important long-term outcomes such as illicit sub-
stance abuse behavior, retention in treatment, and side
effects; we will not be including studies whose primary ob-
jective is to determine dosing and detoxification effects or
precipitated withdrawal. Our primary concern is the influ-
ence of OSTs on retention in treatment and restraining
continued opioid use. We are not interested in studies
determining the effectiveness of OSTs on other substances
such as cocaine or alcohol. We will not include pilot studies
or RCTs at phases 0, 1, and 2. We will review any studies
indexed within the databases allotted time frame and no
restrictions on publication date will be set. All studies
selected for inclusion into the manuscript will be required
to demonstrate appropriate ethics committee approval in
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Declaration. This investigation will not require direct
human experimentation; however, we will still comply
with all objectives of the Helsinki Declaration.
Quality assessment of individual studies
Two authors (LN and BD) will independently conduct a
methodological quality assessment of the studies se-
lected for the systematic review. We will use the
Newcastle-Ottawa Scale (NOS) for observational stud-
ies to assess the risk of bias [44]. We will use the
Cochrane risk of bias tool to assess the risk of bias for
RCTs [45]. Discussions will be used to resolve any
discrepancies that should arise. A third author (ZS)
will be contacted to facilitate resolution in the case
that a mutual consensus is not reached. When asses-
sing risk of bias using the Cochrane tool for RCTs,
scores of 1, 2, or 3 will be assigned for each domain
that is ranked as ‘low risk’, ‘unclear’, or ‘high risk’ of
bias, respectively. Scores from all the domains addressed
by the Cochrane risk of bias tool will be added to give a
total score out of 18, with higher scores indicating a
higher risk of bias. When assessing risk of bias using the
modified Newcastle Ottawa Scale for observational stud-
ies, scores of 1, 2, or 3 will be assigned for domains ranked
as ‘high risk’, ‘unclear’, or ‘low risk’ of bias. Scores from all
the domains will be totaled to a score of 21, with higher
scores indicating lower risk of bias.
Outcome measures
This systematic review will compare methadone, bupre-
norphine/naloxone, naltrexone, and HAT among other
substitute opioid therapies in terms of retention and
response to treatment (as measured through continued
opioid use). Retention in treatment has multiple defini-
tions and measurements across studies, where some chose
to define retention as a continuous value such as the num-
ber of days a patient continued in treatment until the last
day of receiving an intervention receipt [46]; other studies
chose to measure retention as a binary outcome such as
the percentage of patients who completed their treatment
course [47]; and lastly, some studies chose to report the
number of patients who received the treatment for a pre-
defined number of treatment days [39]. Due to the numer-
ous ways retention is defined, measured, and reported, we
will collect any information the articles offer on patient
retention. We will statistically combine results from studies
that similarly report, measure, and define retention. We will
contact authors of studies who uniquely measure/report
patient retention results in an effort to obtain results in the
more commonly defined retention method.
Furthermore, we define response to treatment as abstin-
ence from use of illicit opioids as indicated by absence
of any opioids not pertaining to the treatment in urinetoxicology screening. We will compare the percentage
of opioid-negative urine samples between treatments,
calculated by dividing the number of opioid-negative
urine screens by the total number of urine samples
provided as used in the studies by Mattick et al. (2003)
and Samaan et al. (2014) [48,49]. Please refer to Table 2
for detailed information on how these variables are de-
fined and measured in the current literature.
Data abstraction
For the purpose of this review, we will construct full-
text extraction forms. Data will be later transferred from
these forms and entered into a Microsoft Excel 2011
document. The data abstraction forms were pilot tested
in duplicate to ensure their feasibility in this review.
These forms are available upon request. Any contention
that arises during the extraction process will be resolved
through discussion, and if necessary, a third author (ZS)
will be brought in. The data extraction forms will allow
us to adequately manage the large amount of information
being extracted from individual studies. This information
includes: title of the journal, number of study participants,
study methodology (i.e. RCT and cohort), participant
mean age, outcomes assessed, methods of statistical
measurement, covariates measured in regression models,
outcome statistical association value, p-value, confidence
intervals, data quality (i.e. percentage of missing data and
how missing data were handled), and methods used to
correct for multiple testing.
Statistical analysis plan
When summarizing the evidence of multiple therapies,
we often find that there are a limited number of studies
providing direct comparisons. For example, a number of
systematic reviews compare new therapies (i.e. Naltrexone
and heroin-assisted treatment) only to placebo or the
standard of care, this being methadone. Using novel statis-
tical approaches to multiple treatment comparisons (MTC)
such as the network meta-analysis (NMA), we will provide
the pooled effect estimates of all OSTs for continued opioid
abuse and patient retention, disseminating both direct and
indirect comparisons of all therapies. The results of this re-
view will be summarized both narratively and statistically
where possible. For this review, we will provide summary
estimates (pooled odds ratios for binary outcomes and
standardized mean differences for continuous outcomes)
calculated using direct and indirect sources of evidence,
as well as those arising from mixing both direct and in-
direct evidence, provided the assumption of consistency
is reasonable.
Due to the stark differences in methodology, we will
not be pooling data retrieved from observational stud-
ies with data from RCTs. All direct estimates will be
pooled separately based on study design (randomized
Table 2 Definitions of outcomes in opioid substitution investigations






Continued illicit drug abuse Abstaining from illicit opioid use
throughout treatment.
-Urine toxicology screening OR, rate ratio [39,46,47,50,51]
-Self-reported drug use
Retention in treatment Proportion or participants
completing treatment and days in
treatment from beginning of the
study until the last day of therapy.
-Number of days patient
remains in treatment (days)
Comparing means (SD), HR,
adjusted HR using Cox model,
rate ratio, Kaplan-Meier estimator
[39,47,52-54]
Adverse events Reaction to drugs and/or change




-Randomly recorded at visits
-Total number of adverse
events per day
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differences in treatment estimates obtained from well-
designed observational research do not differ greatly
from RCTs of the same topic [55,56], pooling data from
observational studies and RCTs is highly cautioned
against [57,58]. This separation stems largely from the
inherent differences between RCTs and observational
designs, whereby non-randomized designs face high
susceptibility to selection bias [57].
Direct comparisons
Direct evidence will be pooled using a random-effect
meta-analysis with Knapp-Hartung (KH) estimator [59].
All analyses will be performed using the metafor and
rmeta packages in R [60].
Pooled results from the direct comparisons will be
presented in forest plots. The most commonly used
estimator is DerSimonian-Laird (DL) and is most often
the default estimator in statistical software packages
like Review Manager [61]. The DL estimator is demon-
strated to be inadequate in capturing study heterogeneity,
producing narrow confidence intervals and over-inflating
treatment effects [61,62]. The KH estimator works on
assumptions that variances are estimated from small
samples, in addition to constructing confidence inter-
vals based on the t-distribution (with k-1 degrees of
freedom) [59,63]. Direct comparisons will weight stud-
ies eligible for inclusion using the inverse of the
variance. For the direct comparison meta-analyses
pooling the results from studies investigating retention
in treatment, data will be pooled using risk ratios. The
standardized mean difference will be used when pooling
the results of studies investigating continued opioid abuse
when measured as a continuous variable (mean number
of opioid-positive urine screens per treatment arm). Pro-
vided we have an appropriate number of studies, we will
use an Egger's plot to assess for publication bias.We anticipate differences in outcome measurement
and methodological quality to be important factors for
explaining heterogeneity. These differences will be captured
in our methodological quality assessment using the modi-
fied Newcastle-Ottawa Scale for observational studies and
the Cochrane risk of bias tool for RCTs. Scores from these
tools are determined from a thorough assessment of study
design features such as: sampling strategy, methodological
design (e.g. blinding), and outcome measurement (e.g.
urine toxicology screening vs self-report). We will conduct
subgroup analyses to address the robustness of our results
when stratified by methodology quality based on the risk
bias assessment scores. Studies will be separated into ‘high
and low’ quality based on their scoring, where studies
scoring 5 or lower on the Newcastle Ottawa scale and 6
points or higher on the Cochrane risk of bias tool will be
assessed. These are standard methodological scoring cut
offs used in previous reviews [64]. Provided the data is
suitable, we will perform subgroup analyses based on the
scoring procedures described above.
Some studies suggest using an I2 test statistic cut off
of 40% or greater as an indication of heterogeneity among
the pooled studies [57]; however, using such thresholds
may be ‘misleading’ since heterogeneity represented in the
I2 statistic is influenced by multiple factors [57]. We will
rely on multiple thresholds set forth by the Cochrane
Collaboration to aid in our I2 statistic interpretation,
these include I2 of 0%–40% (might not be important),
30%–60% (moderate heterogeneity), 50%–90% (sub-
stantial heterogeneity), and 75%–100% (considerable
heterogeneity) [57].
Direct and indirect evidence: the network meta-analysis
We propose using a Bayesian hierarchical model for
binary outcomes, where we can account for sampling
variability, treatment heterogeneity, and inconsistency
while also applying maximum likelihood estimation [65].
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allows for an additional random effect, representing
change in the treatment effect as a result of the compari-
son being made [65]. Variation in this random effect
across comparisons will be interpreted as inconsistency
[65]. Assumptions guiding NMA dictate that trials must
be equivalent in their study design and population selec-
tion or the statistical results may be compromised [66];
thus, we will only be including evidence from RCTs into
the NMA model. When trials evaluating a specific treat-
ment are fundamentally distinct from other trials within
that collection, the statistical results may be compromised
by inconsistency [66]. To identify inconsistency, we will
compare direct and indirect evidence using an approach
known as node splitting [67,68]. Comparing inconsistency
using this approach allows us to identify the loops with
large inconsistency and ultimately consider this during in-
terpretation of the results. Within the Bayesian framework,
we will also use the deviance information criterion (DIC)
to inform how parsimonious the data are, with a lower
value being desired [67].
Provided the data is suitable, we will also address in-
consistency using meta-regression to adjust for covari-
ates (effect modifiers) across studies. We will perform a
regression using study level data such as OST dose (mg/
day), publication date, or study design features (blinding)
to examine the improve or change in model fit after co-
variates are included into the model [67].
We will present our results with probability statements
of treatment effects, by which ranking these probabilities
allows the advantage of clarifying the sometimes over-
complex reporting of pairwise p-values [69]. Ranking
probabilities allows us to disseminate as a chance per-
centage, which treatment ranks the highest [69]. After
displaying these rank probabilities graphically, we will
construct the surface under the cumulative ranking
(SUCRA) line for each treatment, in an effort to the
graphically displayed probability ranks [69].
GRADE framework
We will assess the summary estimates of this investigation
using the Grading of Recommendations Assessment,
Development and Evaluation (GRADE) guidelines [70].
Both direct and indirect estimates obtained from the
NMA will be subject to thorough review using the GRADE
framework. Evidence from indirect comparisons will
be subject to additional scrutiny due to our inability to
reliably show that the features of trial design (participants,
interventions, outcome measures) are not impacting the
observed treatment effect [71].
Discussion
We anticipate disseminating an objective review of the
current available literature on the effectiveness of allsubstitute opioid therapies for the treatment of opioid
use disorder. This review will allow us to evaluate not
only the relationship between all substitute opioid ther-
apies and the patient important outcomes, but also, this
review will allow us to evaluate the methodological qual-
ity of current available evidence. We seek to understand
whether there are inconsistencies in the research and
what reasons may account for them. Gaining insight into
the predictors of patient response characteristics in opioid
use disorder will help physicians develop patient-centered
treatment regimes. This will be the first systematic review
available in the literature looking at all possible substitute
opioid therapies at one time. Thus, the dissemination of
these results is imperative to the further enhancement of
clinical practice through guideline development.
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